Intravenous pentamidine is effective as second line <i>Pneumocystis</i> pneumonia prophylaxis in pediatric oncology patients

Abstract

The use of intravenous pentamidine as PCP prophylaxis results in a breakthrough rate of 1.3%. TMP-SMZ is the first choice for PCP prophylaxis. However, when necessary, the use of intravenous pentamidine has an acceptably low failure rate, even in high-risk BMT patients. Other options should be considered for children less than 2 years of age.